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Abstract
Starting from racemic naringenin ((±)-1), a mixture of dracocephin A stereoisomers 6-(2”-pyrrolidinone-5”-yl)naringenin (±)-2a–d
and its regioisomer, dracocephin B 8-(2”-pyrrolidinone-5”-yl)naringenin (±)-3a–d originally isolated from Dracocephalum
rupestre, have been synthesized in a one-pot reaction. The separation of 2a–d and 3a–d was achieved by preparative HPLC. The
four stereoisomers of each natural product were separated by analytical chiral HPLC and their absolute configuration was studied
by the combination of HPLC–ECD measurements and TDDFT–ECD calculations. The synthesized flavonoid alkaloids were further
characterized by physicochemical and in vitro pharmacological studies.
Introduction
Flavonoid alkaloids are a small subgroup of flavonoids
possessing a five- or six-membered nitrogen heterocycle at-
tached to C-6 or C-8 of ring A of the flavonoid moiety. They
have been reported to exhibit a wide range of pharmacological
activities [1]. Dracocephins A and B were isolated as a mixture
of four stereoisomers by Ren et al. in 2008 from Draco-
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
2524
Figure 1: Structures of (±)-naringenin, (±)-dracocephins A1–A4 and B1–B4 with the indication of the absolute configuration and elution orders for sep-
aration on Chiralpak AS-H* column [2]. The absolute configurations are presented as proposed by Ren et al. [2].
Scheme 1: Proposed biosynthetic route to dracocephins A and B.
cephalum rupestre [2], which is an herb widely distributed
throughout western China and used in folk medicine for the
treatment of various conditions including cold, cough, ictero-
hepatitis and laryngalgia. Dracocephins A (±)-2a–d and B
(±)-3a–d have been found to be conjugates of racemic narin-
genin ((±)-1) with pyrrolidine-2-one with C-6–C-5” and
C-8–C-5” linkage, respectively. Due to the two chirality
centers, four possible stereoisomers exist for each regioisomer,
and accordingly, the isolated substances were verified to be 1:1
mixtures of two diastereoisomeric racemates (2a, 2c/2b, 2d; 3a,
3c/3b, 3d) by HPLC–ECD analysis (Figure 1).
The planar structure and absolute configuration of the first-
eluted stereoisomer of dracocephins A (±)-2a–d was deter-
mined by single-crystal X-ray diffraction analysis as (2R,5”S)-
2a [2]. The biosynthesis of these flavonoid–pyrrolidone conju-
gates is proposed by Leete [3] and Tanaka et al. [4] to proceed
via an acylaminocarbinol intermediate, which presumably arises
through the Strecker-degradation of the corresponding amino
acids, which is L-glutamine (4) in the case of dracocephins A
and B as shown in Scheme 1.
The spontaneous cyclization of the Strecker aldehyde 5 yields
the acylaminocarbinol intermediate 6, which readily loses water
on protonation, resulting in the N-acyliminium ion 7a/b, a
strong electrophilic reagent.
Results and Discussion
The aim of our work was to synthesize the natural flavonoid
alkaloids 2a–d and 3a–d in a biomimetic scheme in order
to devise an efficient route to these natural products for struc-
ture–activity relationship studies.
First the N-acylaminocarbinol reagent was prepared in the form
of racemic 5-ethoxypyrrolidine-2-one ((±)-9) by the partial
reduction of succinimide (8) with sodium borohydride at 0 °C,
as described in the literature [5] (Scheme 2).
In the next step, dracocephins A (±)-2a–d and B ((±)-3a–d)
were prepared by reacting racemic naringenin ((±)-1) with the
N-acylaminocarbinol ether (±)-9 in the presence of a catalytic
amount of p-toluenesulfonic acid (PTS) in nitromethane at
101 °C for 4 h as shown in Scheme 3.
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
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Scheme 3: Synthesis of (±)-dracocephins A and B (±)-2a–d and (±)-3a–d and the elution order of stereoisomers on a Chiralpak IC* column with the
eluent hexane/MeCN/TFA 97:3:0.1. Absolute configurations and the names of stereoisomers are shown as proposed by Ren et al. [2].
Scheme 2: Synthesis of (±)-5-ethoxypyrrolidine-2-one ((±)-9).
The product was purified by column chromatography resulting
in a mixture of dracocephins A and B as a white crystalline
solid in 64% yield. Although their mixture could not be separat-
ed on silica gel by column chromatography, the two isomeric
products could be separated by preparative HPLC to result in
regioisomers (±)-2a–d and (±)-3a–d as crystalline powders in a
ratio of 43:57, respectively. These data clearly showed that the
reaction took place without notable regioselectivity, which was
in agreement with the observed 58:42 ratio of natural draco-
cephins A and B [2].
The regioisomeric dracocephins A and B were identified by
NMR spectroscopy. The CD3OD solution of compounds
(±)-2a–d showed a cross-peak between the singlet of H-8 and
the multiplet of H-2’ in the 2D NOESY spectrum, which
corroborated the structure of dracocephins A. Moreover, com-
pounds (±)-3a–d showed 2D NOESY cross peaks between
multiplets of the pyrrolidine ring and H-2’, corresponding to
dracocephins B. Aliquots of sample (±)-2a–d and sample
(±)-3a–d were dissolved in DMSO-d6 in order to allow compar-
ison with literature data. The 1H chemical shifts of the herein
synthesized dracocephins A and B showed good agreement with
those of the isolated flavonoid alkaloids [2]. Similarly to the
natural route, no diastereoselectivity occurred in this sequence,
as proven by the separation of the stereoisomers by chiral
HPLC and by the integration or deconvolution of NMR signals
of Hy-3 recorded in CD3OD.
The separation of the stereoisomers of dracocephins A (±)-2a–d
could be achieved by chiral HPLC using an analytical Chiralpak
IC column with the eluent MeCN/2-propanol/TFA 97:3:0.1
(Figure 2).
Four peaks with alternating signs of the ECD signal in the
HPLC–UV and –ECD traces were observed, the integration of
which showed a near 1:1:1:1 ratio of the stereoisomers. The
HPLC–ECD spectra of the separated stereoisomers were re-
corded, which revealed that the first and fourth eluted stereoiso-
mers are enantiomers, as well as the second and third eluted
ones (Figure 2c,d). On the basis of the reported data [2], the
(2S,5”S) and (2R,5”S) absolute configurations were assigned to
the first- and second-eluted stereoisomers 2b and 2a, respec-
tively, while the third and fourth eluted 2c and 2d stereoiso-
mers had (2S,5”R) and (2R,5”R) absolute configuration. The
elution order of stereoisomers 2b and 2a was inverted in our
analysis with Chiralpak IC column compared to the reported
separation using Chiralpak-AS-H [2].
In order to confirm the assignment of the absolute configura-
tions for the stereoisomers 2a–d independently from the results
of Ren et al. and to test the applicability of the ECD calcula-
tions for the stereochemical studies of flavanoid alkaloids, the
solution TDDFT–ECD calculation method [6] was applied to
2a–d and 3a–d. For the validation of our computational ap-
proach on flavonoids, the ECD spectra of (R)-naringenin ((R)-
1), the building blocks of dracocephins A and B, were calcu-
lated first with different methods to identify which is able to
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
2526
Figure 2: a) Chiral HPLC–UV and HPLC–ECD traces of dracocephins A (2a–d) using Chiralpak IC column with the eluent MeCN/2-propanol/TFA
97:3:0.1 monitored at 290 nm. b) HPLC–ECD spectra of the first [black: (2S,5”S)-2b or dracocephin A2] and fourth eluted [red: (2R,5”R)-2d or draco-
cephin A4] stereoisomers of dracocephins A. c) HPLC–ECD spectra of the second [black: (2R,5”S)-2a or dracocephin A1] and third eluted [red:
(2S,5”R)-2c or dracocephin A3] stereoisomers of dracocephins A. The absolute configurations were assigned on the basis of the publication of
Ren et al. [2].
reproduce most precisely the experimental ECD transitions.
ECD and VCD calculations of naringenin have been reported
recently by Abbate et al., which could serve as a good basis for
our computational studies [7]. Naringenin is a flavanone deriva-
tive, whose negative 327 nm n–π* Cotton effect (CE) and the
positive 289 nm π–π* CE were correlated with M helicity of the
fused hetero ring and (2R) absolute configuration [8,9]. The
mirror image HPLC–ECD spectra of (R)- and (S)-naringenin
were recorded after separating the enantiomers on a Chiralpack
IA column with the eluent hexane/2-propanol 80:20 (Support-
ing Information File 1, Figure S1).
The initial conformational search of (R)-1 with the Merck Mo-
lecular Force Field (MMFF) and CHCl3 solvent model yielded
8 conformers within a 21 kJ/mol energy window, which were
reoptimized at five different DFT levels [B3LYP/6-31G(d) in
vacuo, B3LYP/TZVP PCM/CHCl3, B97D/TZVP [10,11] PCM/
CHCl3, CAM-B3LYP/TZVP [12,13] PCM/CHCl3 and M06-
2X/TZVP [14,15] PCM/CHCl3]. While the B3LYP and CAM-
B3LYP functionals resulted in 4 low-energy conformers over
2% Boltzmann population with an equatorial C-2 aryl group
near coplanar with the C-2– H-2 bond, the B97D and M06-2X
ones afforded 8 conformers including four high-energy ones
with an axial C-2 aryl group (Supporting Information File 1,
Figures S2, S4, S6, and S8). The four CAM-B3LYP/TZVP
(PCM/CHCl3) conformers (Figure 3) differed mostly in the ori-
entation of the 7- and 4’-OH protons and the condensed hetero
ring had M helicity with envelope conformation and C-2
pointing out of the plane (ωC-8a,O-1,C-2,C-3 = −51.6°,
ωC-8a,C-4a,C-4,C-3 = 0.4° for the lowest-energy conformer).
The C-2 aryl group was nearly coplanar with the C-2–H-2 bond
and the ωH-2,C-2,C-1’,C-2’ torsional angle had values in the range
of –11.0° to –13.7°. The B97D/TZVP PCM/CHCl3 and M06-
2X/TZVP reoptimizations produced four high-energy
conformers having axial C-2 aryl groups with 34.9% and 32.7%
total populations, which apparently overestimated this type of
conformers and were not corroborated by the experimental
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
2527
Figure 3: Structure and population of the low-energy CAM-B3LYP/TZVP PCM/CHCl3 conformers (>2%) of (R)-1.
NMR data. Interestingly, the B97D/TZVP PCM method
achieved good results with the conformationally flexible
12-membered macrolides, dendrolides A–M [11].
The BH&HLYP, CAM-B3LYP, B3LYP and PBE0 functionals
and TZVP basis set were applied for the ECD calculations of
the computed conformers, from which only the BH&HLYP and
CAM-B3LYP could reproduce the highest-wavelength charac-
teristic n-π* transition, signs, relative intensities and shapes of
the other bands, while the other two methods produced much
worse agreement (Figure 4).
Figure 4: Experimental HPLC–ECD spectrum of (R)-naringenin ((R)-1)
compared with the Boltzmann-weighted ECD spectra computed for the
CAM-B3LYP/TZVP PCM/CHCl3 low-energy conformers of (R)-1 at
various levels.
The results of the ECD calculations of naringenin suggested
that the CAM-B3LYP/TZVP (PCM/CHCl3) reoptimization of
the initial conformers and BH&HLYP/TZVP or CAM-B3LYP/
TZVP ECD calculations produce the best agreement and thus
these methods were considered primarily in stereochemical
ECD studies of 2a–d and 3a–d.
The MMFF conformational search of (2R,5’’R)-2d and
(2R,5’’S)-2a resulted in 22 and 23 conformers in a 21 kJ/mol
energy window, respectively, the reoptimization of which at
CAM-B3LYP/TZVP PCM/MeCN level yielded only 2 low-
energy conformers over 2% population (Figure 5 and Figure 6).
In both stereoisomers, hydrogen bonding between the 7-OH and
N–H group fixed the relative orientation of the pyrrolidin-2-one
and the naringenin moieties, and this interaction was also re-
sponsible for the low number of computed conformers. The two
computed conformers had comparable populations and they
differed only in the orientation of the 4’-OH. The flavanone
moiety adopted a conformation similar to that of naringenin.
The Boltzmann-averaged BH&HLYP/TZVP and CAM-
B3LYP/TZVP ECD spectra of (2R,5’’R)-2d and (2R,5’’S)-2a
confirmed the (2R) absolute configuration of the flavanone
units, which was also evident from the negative 330 nm n–π*
CE. The BH&HLYP/TZVP and CAM-B3LYP/TZVP ECD
spectra of (2R,5’’R)-2d showed a better agreement with the
ECD of 2a (second-eluted stereoisomer) on the basis of the
agreement with the 202 nm positive CE but the negative
330 nm n–π* transition was missing from the computed ECDs.
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
2528
Figure 5: Structure and population of the low-energy CAM-B3LYP/TZVP PCM/MeCN conformers (>2%) of (2R,5’’R)-2d.
Figure 6: Structure and population of the low-energy CAM-B3LYP/TZVP PCM/MeCN conformers (>2%) of (2R,5’’S)-2a.
The negative 330 nm n–π* transition could be only reproduced
by the B97D/TZVP conformers (Supporting Information File 1,
Figure S15), which, however, contained 28.1% total population
of conformers with an axial C-2 aryl group and the overall
agreement of their computed ECDs were quite bad. The experi-
mental ECD spectra of the epimers (2R,5’’R)-2d and (2R,5’’S)-
2a showed the same negative/positive/negative ECD pattern
from 370 nm to 210 nm and they only had a difference in the
additional positive CE of (2R,5’’S)-2a at 202 nm (Figure 7).
However, it seemed that (2R,5’’R)-2d had also negative CE
below 200 nm, which could not be measured precisely due to
the UV cut-off limitation of the 2-propanol eluent. Thus the ex-
perimental HPLC–ECD spectra of (2R,5’’R)-2d and (2R,5’’S)-
2a only showed differences in the position, shape and relative
intensities of the bands, while the patterns of the ECD bands
were identical.
The Boltzmann-averaged BH&HLYP/TZVP and CAM-
B3LYP/TZVP ECD spectra of (2R,5’’S)-2a reproduced well the
negative n–π* 330 nm CE and the intense 213 nm negative CE
of (2R,5’’R)-2d but it changed the sign of CE to positive below
210 nm, which was characteristic of (2R,5’’S)-2a (Figure 8).
Interestingly, the B3LYP/TZVP and PBE0/TZVP ECD spectra
of (2R,5’’S)-2a gave a perfect agreement with the HPLC–ECD
Figure 7: Experimental HPLC-ECD spectra of (2R,5’’S)-2a (second
eluted stereoisomer) and (2R,5’’R)-2d (fourth eluted stereoisomer)
compared with the Boltzmann-weighted ECD spectra computed for the
CAM-B3LYP/TZVP PCM/MeCN low-energy conformers of (2R,5’’R)-2
at various levels.
of (2R,5’’R)-2d (fourth eluted stereoisomer). All these calcula-
tion results would favor the configurational assignment
(2R,5’’S)-2d (fourth eluted stereoisomer) and (2R,5’’R)-2a
(second eluted stereoisomer), which, however, contradicts the
previously published results [2]. From the ECD calculation
point of view, the differences in the HPLC ECD spectra of the
epimers (2R,5’’R)-2d and (2R,5’’S)-2a were not sufficient and
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
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Figure 9: a) Chiral HPLC–UV and HPLC–ECD traces of dracocephins B1–B4 3a–d using a Chiralpak IC column with the eluent MeCN/2-propanol/
TFA 90:10:0.1 monitored at 285 nm. b) HPLC–ECD spectra of the first- [black: (2R,5”S)-3b or dracocephin B2] and fourth eluted [red: (2S,5”R)-3d or
dracocephin B4] stereoisomers of dracocephins B. c) HPLC–ECD spectra of the second [black: (2S,5”S)-3a or dracocephin B1] and third eluted [red:
(2R,5”R)-3c or dracocephin B3] stereoisomers of dracocephins B. The absolute configurations were assigned on the basis of the publication of
Ren et al. [2].
Figure 8: Experimental HPLC–ECD spectra of (2R,5’’S)-2a and
(2R,5’’R)-2d compared with the Boltzmann-weighted ECD spectra
computed for the CAM-B3LYP/TZVP PCM/MeCN low-energy
conformers of (2R,5’’S)-2 at various levels.
the calculation results were not consistent enough to allow the
revision of the previous configurational assignment.
The separation of the stereoisomers of dracocephins B 3a–d
could be performed on an analytical Chiralpak IC column using
the eluent acetonitrile/2-propanol/trifluoroacetic acid 90:10:0.1
(Figure 9a).
Only partial separation could be achieved for the first two
eluting stereosiomers, which was still sufficient to record their
HPLC–ECD spectra. The comparison of HPLC–ECD spectra
showed that the first and fourth eluted stereoisomers were enan-
tiomers as well as the second and third eluted ones. Similarly to
dracochepins A, the elution order was inverted for the first- and
second-eluted stereoisomers compared to that of the reported
data with Chiralpak AS-H [2]. The solution TDDFT-ECD
calculation approach was also applied to the stereoisomers of
dracocephins B 3a–d in order to check the applicability of this
method.
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
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Figure 10: Structure and population of the low-energy CAM-B3LYP/TZVP PCM/MeCN conformers (>2%) of (2R,5’’R)-3c.
Figure 11: Structure and population of the low-energy CAM-B3LYP/TZVP PCM/MeCN conformers (>2%) of (2R,5’’S)-3b.
The MMFF conformational search of (2R,5’’R)-3c and
(2R,5’’S)-3b resulted in 41 and 44 conformers in a 21 kJ/mol
energy window, respectively, the reoptimization of which at
CAM-B3LYP/TZVP PCM/MeCN level yielded 2 low-energy
conformers over 2% population for both stereoisomers
(Figure 10 and Figure 11).
Similarly to dracochepins A (2a–d), hydrogen bonding be-
tween the 7-OH and NH groups anchored the orientation of the
pyrrolidinone moiety. The two conformers differed in the orien-
tation of the two 4’-OH and the C-2 aryl moiety adopted equa-
torial orientation with M helicity and envelope conformation of
the condensed heteroring.
The calculated Boltzmann-averaged ECD spectra of (2R,5’’R)-
3c and (2R,5’’S)-3b verified the (2R) absolute configuration of
the third-eluted and second-eluted stereoisomers on the basis of
the high-wavelength negative n–π* and positive π–π* CEs and
the BH&HLYP and CAM-B3LYP functionals could reproduce
the negative n–π* transition (Figure 12).
The absolute configuration of C-5” could not be unambiguous-
ly deduced from the calculations. The BH&HLYP and CAM-
Figure 12: Experimental HPLC-ECD spectra of 3b (first eluted stereo-
isomer) and 3c (third eluted stereoisomer) compared with the Boltz-
mann-weighted ECD spectra computed for the CAM-B3LYP/TZVP
PCM/MeCN low-energy conformers of (2R,5’’R)-3 at various levels.
B3LYP ECD spectra of (2R,5’’R)-3c had a weak positive CE at
about 250 nm, which was missing from the experimental curve
and they rather resembled the HPLC-ECD curve of the first-
eluted stereoisomer. The BH&HLYP and CAM-B3LYP ECD
spectra of (2R,5’’S)-3 reproduced quite well the signs and posi-
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
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Figure 14: Proposed mechanism for the formation of dracocephins A and B (2a–d and 3a–d) starting from (±)-9.
Table 1: Calculated and measured medicinal chemical parameters of dracocephins A and B compared to those of naringenin.















2.39 ± 0.02 1.51/2.12 116.1 non-permeable
tion of the experimental ECD bands, although the intensity of
the 201 negative CE was overestimated (Figure 13).
Figure 13: Experimental HPLC-ECD spectra of 3b and 3c compared
with the Boltzmann-weighted ECD spectra computed for the CAM-
B3LYP/TZVP PCM/MeCN low-energy conformers of (2R,5’’S)-3 at
various levels.
Similarly to dracocephins A (2a–d), ECD spectra computed for
(2R,5’’S)-3 with B3LYP and PBE0 functionals resembled more
the experimental HPLC–ECD spectrum of 3c than that of 3b.
A plausible mechanism for the formation of dracochepins A and
B involves the electrophilic attack of the N-acyliminium ion
7a,b on the aromatic ring A of racemic naringenin ((±)-1) at
C-6 and C-8 (Figure 14).
The electrophilic reagent arises from the amidocarbinol ether
(±)-9 after protonation and loss of ethanol. The planar structure
of the cation explains the lack of stereoselectivity observed in
the reaction.
Physicochemical measurements
Physicochemical characterization of dracocephins A and B was
also carried out. The relevant calculated (total polar surface
area; TPSA) and measured (pKa, log P/D and Pe) parameters
are shown in Table 1. The lipophilicity of neutral species of
naringenin and dracocephins A and B are 3.39, 2.52 and 2.39,
respectively. Similarly to this lipophilicity trend, the TPSA
value of (±)-naringenin is lower than dracocephins A and B,
however, there is no difference between the calculated TPSA
values of 2a–d and 3a–d. The pKa values of the three phenolic
hydroxy groups of the evaluated compounds are quite similar
and these are in the range of 6.5 and 12.0. Among these proton-
dissociation constants, the lowest acidic pKa values are predom-
inant in physiological environment, which is also indicated by
Beilstein J. Org. Chem. 2016, 12, 2523–2534.
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the difference of log D values between pH 7.4 and pH 6.5. The
blood–brain barrier (BBB) specific penetration of dracocephins
isomers has also been studied by the PAMPA (parallel artificial
membrane permeability assay)-BBB model system, which indi-
cates passive diffusion of test compounds across the brain capil-
lary endothelium. Although naringenin ((±)-1) showed a medi-
um penetration characteristic in this model system, draco-
cephins A (2a–d) and B (3a–d) had been described as poorly
and practically non-permeable compounds, respectively. These
results are in good correlation with a lower lipophilicity
(log P/D7.4) and higher TPSA of dracocephins A and B com-
pared to that of naringenin.
Pharmacological studies
In connection with the BBB penetration studies, 2a–d and 3a–d
were tested for their potential towards CNS cytotoxic activity
on undifferentiated SH-SY5Y neuroblastoma cells. None of the
two isomeric compounds exerted cytotoxicity on this cell line
(IC50 > 150 μM for both compounds), which rules out their
potential CNS antitumor activity and it also suggests them as
non-neurotoxic substances. On the other hand, the possibility
for neuroprotective activity could not be tested with the applied
experimental setup. As an additional bioassay on compounds
2a–d and 3a–d, their potential to interfere with the function of
P-glycoprotein (P-gp) was tested. By transporting a wide
variety of compounds from the CNS back into the blood stream,
P-gp is an important element of the BBB [16]. Naringenin is
known to interfere with the BBB penetration of vincristine, a
P-gp substrate, through modulating this efflux pump [17], and
an additional nitrogen-containing group has the chance to sig-
nificantly increase P-gp inhibitory activity [18]. Based on the
unaltered accumulation of rhodamine 123, a P-gp substrate
fluorescent dye, in the P-gp transfected L5178MDR cells, we ob-
served that none of the synthesized compounds inhibits this
transporter. The antioxidant activity of dracocephins A and B
was also measured, but these compounds, along with narin-
genin were virtually inactive in the DPPH radical scavenging
test (IC50 > 200 µg/mL), compared to the positive control
quercetin (IC50 = 9.4 ± 0.6 µg/mL).
Conclusion
An efficient one pot synthesis of dracocephins A (2a–d) and B
(3a–d) was achieved starting from racemic naringenin ((±)-1),
using the readily accessible N-acylaminocarbinol reagent (+)-9).
The regioisomeric dracochepins A and B could be separated by
preparative HPLC and their connectivity was determined on the
basis of NMR data. Stereoisomers of dracocephins A (2a–d)
and B (3a–d) were separated by chiral HPLC and their stereo-
chemistry was studied by TDDFT-ECD calculations. By testing
different methods for the calculation of conformers and ECD,
the configurational assignment of C-2 of the flavanone moiety
could be confirmed, while the C-5” of the pyrrolidinone unit
could not be assigned unambiguously. Dracocephins A (2a–d)
and B (3a–d) were also characterized by physicochemical and
in vitro biological measurements. A plausible mechanism of the
synthesis of these natural products was also proposed.
Experimental
General
Melting points were measured on a SANYO Gallenkamp appa-
ratus and are uncorrected. IR spectra were recorded on a Bruker
FTIR instrument. NMR measurements (1H, 13C, gCOSY, 1D
NOESY and 2D NOESY, gHSQCAD, gHMBCAD) were per-
formed on Varian 400 MHz (equipped with 5 mm OneNMR
15N-31P/{1H-19F} PFG Probe), Varian 500 MHz (equipped
with 1H{13C/15N} 5 mm PFG Triple Resonance 13C Enhanced
Cold Probe) and Varian 800 MHz (equipped with 1H{13C/15N}
Triple Resonance 13C Enhanced Salt Tolerant Cold Probe)
spectrometers. 1H chemical shifts are given on the delta scale as
parts per million (ppm) with tetramethylsilane (TMS) as the
internal standard (0.00 ppm). 13C chemical shifts are given on
the delta scale as parts per million (ppm) with tetramethylsilane
(TMS) or dimethylsulfoxide-d6 as the internal standard
(0.0 ppm and 39.5 ppm, respectively). MS spectra were re-
corded on VG-Trio-2 and Finnigan MAT 95SQ instruments
using EI or ESI techniques. HRMS analyses were performed on
an LTQ FT Ultra (Thermo Fischer Scientific, Bremen,
Germany) system. TLC was carried out on TLC Silicagel 60
F254 on 20 × 20 aluminium sheets (Merck) and preparative TLC
was performed using Silicagel 60 F254+366 (Merck) coated glass
plates. Column chromatography was performed using Geduran
Si 60 (Merck) silica. Racemic naringenin was purchased from
Sigma-Aldrich and used without further purification.
Preparative HPLC
Chemicals and reagents
Acetonitrile used in the preparative chromatographic separation
was gradient grade LiChrosolv purchased from Merck. The
formic acid was reagent grade from Sigma-Aldrich. Water was
purified with a Milli-Q system. The sample solvent was spec-
troscopy grade dimethyl sulfoxide (Uvasol) from Merck.
Apparatus
The separation of the isomeric mixtures of flavonoid alkaloids
was performed with a Shimadzu chromatograph equipped with
an LC-8A pump unit, SPD-M20A Photodiode detector and
CBM-20A system controller. The samples were introduced via
an SIL-10AP sample injector and the chromatograms were
processed using the LCsolution software. The fractions were
collected by an FRC10A fraction collector module. The
temperature was controlled by a CTO-20AC prominence
column oven.
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Preparative separation procedure
The sample (500 µL/injection) was loaded to a Kinetex 5 µm
phenyl-hexyl AXIA packed 21.2 × 150 mm column in the
concentration of 20 mg/mL. The separation was achieved
with isocratic elution (75% HPLC grade water containing
0.1% formic acid, 25% acetonitrile containing 0.1%
formic acid) at 25 °C. The flow rate was 21 mL/min. The frac-
tions were collected based on UV absorption at 220 nm wave-
length.
Chiral HPLC–ECD analysis
Chiral HPLC separations were carried out with a Jasco HPLC
system on Chiralpak IC column (250 × 4.6 mm i.d.; 5 μm)
using eluent hexane/acetonitrile 97:3 or 90:10 with 0.1% TFA
additive to set the pH to about 2 at a flow rate of 1.0 mL/min for
2 and 3. HPLC–UV and OR chromatograms were measured
with Jasco MD-910 multiwavelength and OR-2090Plus chiral
detectors, respectively. The HPLC–ECD traces were recorded
at the specified wavelength with a Jasco J-810 CD spectropo-
larimeter equipped with a 1 cm HPLC flow cell and the base-
line was zeroed after the start of each run. The on-line ECD and
UV spectra were recorded simultaneously by stopping the flow
at the UV absorption maximum of each peak. ECD ellipticity
values (Φ) were not corrected for concentration. For an
HPLC–ECD spectrum, three consecutive scans were recorded
and averaged with 2 nm bandwidth, 1 s response, and standard
sensitivity. The HPLC–ECD spectrum of the eluent was re-
corded in the same way. The concentration of the injected sam-
ple was set so that the HT (voltage) value did not exceed 500 V
in the HT channel.
Dracocephins A1–A4 (2ª–d): 2b (first eluted stereoisomer):
tR = 7.26 min, λ [nm] (Φ)}: 330 (4.43), 288 (–15.34), 249sh
(2.48), 230 (11.60), 213 (27.01). 2a (second eluted stereoiso-
mer): tR = 7.49 min, λ [nm] (Φ)}: 329 (–3.95), 289 (13.60),
250sh (–2.18), 227 (–7.35), 202 (15.98). 2c (third eluted stereo-
isomer): tR  = 11.49 min, λ  [nm] (Φ)}: 329 (1.92),
289 (–7.86), 250sh (1.09), 227 (4.56), 202 (–10.49). 2d
(fourth eluted stereoisomer): tR = 12.38 min, λ [nm] (Φ)}: 330
(–5.71), 288 (17.65), 249sh (–3.54), 230sh (–17.68), 213
(–33.89).
Dracocephins B1–B4 (3a–d): 3b (first peak): tR = 4.87 min, λ
[nm] (Φ)}: 327 (–2.15), 288 (8.40), 252sh (–0.88), 234sh
(–2.24), 221 (–5.07), 201 (19.79). 3a (second peak): tR = 4.87
min, λ [nm] (Φ)}: 332 (0.65), 290 (–2.74), 254 (0.13), 240sh
(0.90), 203 (18.81). 3c (third peak): tR = 5.53 min, λ [nm] (Φ)}:
328 (–1.02), 288 (6.25), 254 (–0.42), 235sh (–2.14), 203
(–11.47). 3d (fourth peak): tR = 7.56 min, λ [nm] (Φ)}: 328
(1.02), 288 (–4.68), 252sh (0.17), 234sh (0.42), 221 (1.46), 201
(–9.10).
(±)-Naringenin ((±)-1): (2R)-1 (first peak) tR = 5.19 min on a
Chiralpak IA column (hexane/2-propanol 80:20), λ [nm] (Φ)}:
327 (–6.75), 314sh (–4,02), 289 (28.91), 235sh (–7.96), 215
(–28.48); (2S)-1 (second peak): tR = 5.84 min on a Chiralpak IA
column (hexane/2-propanol 80, λ [nm] (Φ)}: 327 (5.49), 314sh
(3.49), 289 (–22.65), 235sh (4.69), 215 (21.67).
Preparation of dracocephins A ((±)-2a–d) and
B ((±)-3a–d)
To a suspension of racemic naringenin [(±)-1] (200 mg,
0.735 mmol) in nitromethane (5 mL) was added 5-ethoxypyrro-
lidine-2-one ((±)-9, 114 mg, 0.883 mmol), a catalytic amount of
p-toluenesulfonic acid and the mixture was refluxed for 4 h.
The solvent was evaporated in vacuo and the solid residue was
purified by column chromatography (CH2Cl2/CH3OH = 10:1).
An isomeric mixture of (±)-2a–d and (±)-3a–d (168 mg, 64%)
was obtained as a white crystalline solid, Rf (CH2Cl2:CH3OH =
10:1) 0.32. A sample of the mixture (47 mg) was subjected to
further purification by preparative HPLC, which gave title com-
pounds (±)-2a–d (16 mg, 99.66% purity) as a white solid, mp
168–170 °C; IR (KBr) νmax: 3393, 3034, 2970, 1634, 1519,
1455, 1340, 1310, 1279, 1170, 1090 cm−1; 1H NMR (799.7
MHz, CD3OD) δH 2.21–2.27 (m, 1H, Hx-4”), 2.36–2.42 (m,
1H, Hx-3”), 2.43–2.49 (m, 1H, Hy-4”), 2.59–2.64 (m, 1H,
Hy-3”), 2.71–2.75 (m, 1H, Hx-3), 3.12 and 3.13 [sum 1H, (dd, J
= 17.0, 12.8 Hz, Hy-3A) and (dd, J = 17.0, 12.6 Hz, Hy-3B), re-
spectively], 5.33–5.36 (buried m, 2H, H-5” and H-2), 5.95 (s,
1H, H-8), 6.80–6.82 (m, 2H, H-3’ and H-5’), 7.29–7.32 (m, 2H,
H-2’ and H-6’); 13C NMR (201.1 MHz, CD3OD) δC 26.7
(C-4”), 32.07 and 32.10 (C-3”), 43.96 and 43.99 (C-3), 49.4
(C-5”), 80.52 and 80.53 (C-2), 96.04 and 96.06 (C-8), 103.1
(C-10), 109.44 and 109.46 (C-6), 116.4 (C-3’ and C-5’), 129.09
and 129.10 (C-2’ and C-6’), 131.0 (C-1’), 159.12 and 159.13
(C-4’), 163.47 and 163.50 (C-5), 163.90 and 163.91 (C-9),
166.8 (C-7), 181.60 and 181.63 (C-2”), 198.1 (C-4); HRMS [M
+ H] calcd for C19H18O6N: 356.11286; found: 356.11284;
ESI–MS–MS (CID = 35%) (rel. int. %): 339(100); 338(4);
311(2); 236(3); and title compounds (±)-3a–d (21 mg, 99.92%
purity), also a white solid, mp 238–240 °C; IR (KBr) νmax:
3416, 3034, 2970, 1630, 1519, 1447, 1378, 1343, 1257, 1176,
1081 cm−1; 1H NMR (799.7 MHz, CDCl3:CD3OD = 2:1) δH
2.15–2.29 (buried m, 2H, Hx-3” and Hx-4”), 2.30–2.37 (m, 1H,
Hy-3”), 2.38–2.46 (m, 1H, Hy-4”), 2.73–2.79 (m, 1H, Hx-3),
3.09 and 3.14 [sum 1H, (dd, J = 17.0, 13.1 Hz, Hy-3A) and (dd,
J = 17.1, 13.2 Hz, Hy-3B), respectively], 5.28–5.37 (buried m,
2H, H-5” and H-2), 6.00 (s, 1H, H-6), 6.87–6.90 (m, 2H, H-3’
and H-5’), 7.28–7.31 (m, 2H, H-2’ and H-6’); 13C NMR (201.1
MHz, CD3OD) δC 25.8 and 25.9 (C-4”), 31.1 (C-3”), 42.8 and
43.5 (C-3), 48.4 and 48.6 (C-5”), 79.7 and 80.0 (C-2), 96.6
(C-6), 102.6 (C-10), 107.9 (C-8), 115.9 (C-3’ and C-5’), 128.2
(C-2’ and C-6’), 129.3 (C-1’), 158.0 (C-4’), 161.9 (C-9), 163.4*
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(C-5), 165.6* (C-7), 180.2 (C-2”), 196.9 and 197.0 (C-4); (*:
may be reversed); HRMS [M + H]: calcd for C19H18O6N
356.11286; found: 356.11285; ESI–MS–MS (CID = 35%) (rel.
int. %): 339 (100); 338 (4); 311 (3); 236 (6).
Supporting Information
Supporting Information File 1
Details of physicochemical measurements, biology and
computational section, computed ECD spectra, conformers





The authors are grateful to Gedeon Richter Plc. for the finan-
cial support, and to Prof. Joseph Molnár (Department of
Medical Microbiology and Immunobiology, University of
Szeged, Szeged, Hungary) for generously providing cell lines
for the bioassays. Á. Szappanos, A. Mándi, S. Antus and T.
Kurtán gratefully acknowledge the support provided by OTKA/
NKFI (Grant Nos: K-112951, K-105871 and PD 121020) and
the CPU time by the National Information Infrastructure Devel-
opment Institute (NIIFI 10038).
References
1. Khadem, S.; Marles, R. J. Molecules 2012, 17, 191–206.
doi:10.3390/molecules17010191
2. Ren, D.-M.; Guo, H.-F.; Yu, W.-T.; Wang, S.-Q.; Ji, M.; Lou, H.-X.
Phytochemistry 2008, 69, 1425–1433.
doi:10.1016/j.phytochem.2008.01.013
3. Leete, E. J. Nat. Prod. 1982, 45, 605–607. doi:10.1021/np50023a015
4. Tanaka, T.; Watarumi, S.; Fujieda, M.; Kouno, I. Food Chem. 2005, 93,
81–87. doi:10.1016/j.foodchem.2004.09.013
5. Ilkei, V.; Bana, P.; Tóth, F.; Palló, A.; Holczbauer, T.; Czugler, M.;
Sánta, Z.; Dékány, M.; Szigetvári, Á.; Hazai, L.; Szántay, C., Jr.;
Szántay, C.; Kalaus, G. Tetrahedron 2015, 71, 9579–9586.
doi:10.1016/j.tet.2015.10.020
6. Tóth, L.; Fu, Y.; Zhang, H. Y.; Mándi, A.; Kövér, K. E.; Illyés, T.-Z.;
Kiss-Szikszai, A.; Balogh, B.; Kurtán, T.; Antus, S.; Mátyus, P.
Beilstein J. Org. Chem. 2014, 10, 2594–2602. doi:10.3762/bjoc.10.272
7. Abbate, S.; Burgi, L. F.; Castiglioni, E.; Lebon, F.; Longhi, G.;
Toscana, E.; Caccamese, S. Chirality 2009, 21, 436–441.
doi:10.1002/chir.20616
8. Slade, D.; Ferreira, D.; Marais, J. P. J. Phytochemistry 2005, 66,
2177–2215. doi:10.1016/j.phytochem.2005.02.002
9. Gaffield, W. Tetrahedron 1970, 26, 4093–4108.
doi:10.1016/S0040-4020(01)93050-9
10. Grimme, S. J. Comput. Chem. 2006, 27, 1787–1799.
doi:10.1002/jcc.20495
11. Sun, P.; Xu, D.-X.; Mándi, A.; Kurtán, T.; Li, T.-J.; Schulz, B.;
Zhang, W. J. Org. Chem. 2013, 78, 7030–7047. doi:10.1021/jo400861j
12. Yanai, T.; Tew, D. P.; Handy, N. C. Chem. Phys. Lett. 2004, 393,
51–57. doi:10.1016/j.cplett.2004.06.011
13. Pescitelli, G.; Di Bari, L.; Berova, N. Chem. Soc. Rev. 2011, 40,
4603–4625. doi:10.1039/c1cs15036g
14. Zhao, Y.; Truhlar, D. G. Theor. Chem. Acc. 2008, 120, 215–241.
doi:10.1007/s00214-007-0310-x
15. Tähtinen, P.; Oja, T.; Dreiack, N.; Mäntsälä, P.; Niemi, J.;
Metsä-Keteläb, M.; Klika, K. D. RSC Adv. 2012, 2, 5098–5100.
doi:10.1039/c2ra20537h
16. Schinkel, A. H. Adv. Drug Delivery Rev. 1999, 36, 179–194.
doi:10.1016/S0169-409X(98)00085-4
17. Mitsunaga, Y.; Takanaga, H.; Matsuo, H.; Naito, M.; Tsuruo, T.;
Ohtani, H.; Sawada, Y. Eur. J. Pharmacol. 2000, 395, 193–201.
doi:10.1016/S0014-2999(00)00180-1
18. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. J. Clin. Pharm. Ther.
2003, 28, 203–228. doi:10.1046/j.1365-2710.2003.00487.x
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic
Chemistry terms and conditions:
(http://www.beilstein-journals.org/bjoc)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjoc.12.247
